首页
/
/
/
脱氢酶
/
Vidofludimus
Vidofludimus
{[allProObj[0].p_purity_real_show]}
货号：A377932
同义名：
4sc-101;SC12267
Vidofludimus 是一种二氢嘧啶脱氢酶（DHODH）抑制剂，IC50 为 134 nM，主要用于治疗免疫相关疾病，如炎症性肠病（IBD），并通过靶向 FXR 研究脂肪肝。
Vidofludimus 化学结构
Vidofludimus 3D分子结构
规格
价格
会员价
库存
数量
{[ item.pr_size ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]}
{[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}
现货
咨询
-
+
Vidofludimus 纯度/质量文件 产品仅供科研
货号：A377932
标准纯度：
{[allProObj[0].p_purity_real_show]}
产品说明书
全球学术期刊中引用的产品
• JMC , 2024. Ambeed. A918471 ,
A995972
]
• Anal. Chem. , 2024, 96(50): 19947-19954. Ambeed. A261947 ,
A1165388
]
• ACS Biomater. Sci. Eng. , 2024. Ambeed. A220462
]
• ACS Biomater. Sci. Eng. , 2024. Ambeed. A165235 ,
A110205
]
• Pharmaceutics , 2024, 16(12): 1546. Ambeed. A272538 ,
A187261 ,
A691302 ,
A506702
]
更多 >
Vidofludimus 质控信息
Trilostane
✔
99+%
AGI-6780
+++
IDH2 R140Q mutant, IC50: 23 nM
99%+
Gimeracil
✔
98%
AGI-5198
++
R132C-IDH1, IC50: 0.16 μM
R132H-IDH1, IC50: 70 nM
99%+
SW033291
++++
15-PGDH, IC50: 1.5 nM
15-PGDH, Ki: 0.1 nM
99%+
Mycophenolic acid
✔
99+%
Fomepizole
✔
98%
Leflunomide
✔
98%
3-Nitropropanoic acid
✔
99%+
Isovaleramide
✔
99%
Mycophenolate Mofetil
+++
Inosine monophosphate dehydrogenase II, IC50: 27 nM
Inosine monophosphate dehydrogenase I, IC50: 39 nM
98%
MK-8245
++++
SCD1 (mouse), IC50: 1 nM
SCD1 (rat), IC50: 3 nM
99%+
Vidofludimus
++
Human DHODH, IC50: 134 nM
99%+
Emodin
✔
98%
Ivosidenib
✔
98%
NCT-501
++
98%
Gossypol
✔
99%+
Devimistat
✔
98%
Disulfiram
✔
98%+
Enasidenib
++++
98%
PluriSIn 1
✔
99%+
ML390
+
99%+
Teriflunomide
✔
99%+
Daidzin
+++
98+%
18β-Glycyrrhetinic acid
✔
99%
RRx-001
✔
95%
NCT-503
+
99%+
Vorasidenib
✔
99%+
Ammonium Glycyrrhizinate(x:1)
✔
98+%
展开
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
Vidofludimus 生物活性
靶点
Dehydrogenase
Human DHODH, IC50:134 nM
描述
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte proliferation in vitro. Ex vivo Vido completely blocked IL-23 + IL-1β-stimulated secretion of IL-17 by colonic strips. In vivo Vido treatment alone most effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells[3] [4] [5]
Vidofludimus 参考文献
[1] Fitzpatrick LR, Small JS, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60.
[2] Kulkarni OP, Sayyed SG, et al. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol. 2010 Jun;176(6):2840-7.
[3] Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60
[4] Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129
[5] Zhu Y, Xu S, Lu Y, Wei Y, Yao B, Guo F, Zheng X, Wang Y, He Y, Jin L, Li Y. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590
展开
Vidofludimus 实验方案
计算器
摩尔计算器
总药量计算器
工作液计算器
存储液制备
1mg
5mg
10mg
1 mM
5 mM
10 mM
2.81mL
0.56mL
0.28mL
14.07mL
2.81mL
1.41mL
28.14mL
5.63mL
2.81mL
Vidofludimus 技术信息
搜索
